Occurrence of Malignancies in Hungarian Patients with Systemic Lupus Erythematosus
Identifieur interne : 001B24 ( Main/Exploration ); précédent : 001B23; suivant : 001B25Occurrence of Malignancies in Hungarian Patients with Systemic Lupus Erythematosus
Auteurs : Tünde Tarr [Hongrie] ; Balázs Gyorfy [Hongrie] ; Éva Szekanecz [Hongrie] ; Harjit Pal Bhattoa [Hongrie] ; Margit Zeher [Hongrie] ; Gyula Szegedi [Hongrie] ; Emese Kiss [Hongrie]Source :
- Annals of the New York Academy of Sciences [ 0077-8923 ] ; 2007-06.
English descriptors
- Teeft :
- Arthritis rheum, Autoimmune, Autoimmune diseases, Bernatsky, Bladder, Breast cancer, Cancer frequency, Cancer morbidity, Cancer prevalence, Cell proliferation, Cervix, Cervix cancer, Cohort, Data show, Debrecen, Direct correlation, Disease duration, Erythematosus, First years, Health science center, Hematologic, Hematologic malignancies, High risk, Hungarian lupus patients, Life expectancy, Lupus, Lupus diagnosis, Lupus onset, Lupus patients, Lymphoma, Lymphoma development, Major determinants, Malignancy, Malignant, Malignant disorders, Morbidity, Particular types, Patient examination, Rheum, Rheumatology, Screening measures, Skin cancer, Standardized incidence ratio, Study period, Such cases, Systemic, Systemic lupus erythematosus, Third department, York academy.
Abstract
abstract: As a result of increasing life expectancy of lupus patients, malignant disorders have become major determinants of morbidity and mortality. The objectives of this study were to analyze cancer‐associated morbidity and mortality, the type of malignancies in Hungarian lupus patients, and to analyze association with immune‐suppressive therapy, disease duration, and age of the patients. Data from 860 systemic lupus erythematosus (SLE) patients were retrospectively analyzed in a study period between 1970 and 2004. Results were compared to data from age‐ and sex‐matched population obtained from the Health for All database, and also to literature data. A total of 37 patients presented with cancer, reflecting 4.3% cancer‐associated morbidity. Patients were 47 (20–73) years old at the onset of malignancy, which appeared 13 (1–45) years later than SLE. Cancer prevalence was the highest in the first 5–10 years of lupus. Breast cancer was the most common malignancy (n= 11) followed by gastrointestinal tumors (n= 9), cervix cancer and hematologic malignancies (n= 5 for both), bronchial cancer (n= 4), bladder, skin, and ovarian cancer (n= 1 for each). Standardized incidence ratio was the highest for non‐Hodgkin lymphoma (standardized incidence ratio [SIR] 3.5, 95%CI 0.4–12.5) and cervix cancer (SIR 1.7, 95%CI 0.6–4.1). Although 76% of patients with cancer received immune‐suppressive therapy besides corticosteroids, no direct correlation could be confirmed between therapy and malignancy. Out of the 164 patients that expired during the study period, 18 were cancer‐related. As such the cancer‐associated mortality was 11% (18/164). This peaked during the last 4 years of the study period (8/24, 33%). Lupus patients are at high risk for particular types of malignant disorders, highlighting the importance of screening measures and focused patient examination.
Url:
DOI: 10.1196/annals.1422.008
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002B89
- to stream Istex, to step Curation: 002B89
- to stream Istex, to step Checkpoint: 000A07
- to stream Main, to step Merge: 001B35
- to stream Main, to step Curation: 001B24
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Occurrence of Malignancies in Hungarian Patients with Systemic Lupus Erythematosus</title><author><name sortKey="Tarr, Tunde" sort="Tarr, Tunde" uniqKey="Tarr T" first="Tünde" last="Tarr">Tünde Tarr</name></author><author><name sortKey="Gyorfy, Balazs" sort="Gyorfy, Balazs" uniqKey="Gyorfy B" first="Balázs" last="Gyorfy">Balázs Gyorfy</name></author><author><name sortKey="Szekanecz, Eva" sort="Szekanecz, Eva" uniqKey="Szekanecz E" first="Éva" last="Szekanecz">Éva Szekanecz</name></author><author><name sortKey="Bhattoa, Harjit Pal" sort="Bhattoa, Harjit Pal" uniqKey="Bhattoa H" first="Harjit Pal" last="Bhattoa">Harjit Pal Bhattoa</name></author><author><name sortKey="Zeher, Margit" sort="Zeher, Margit" uniqKey="Zeher M" first="Margit" last="Zeher">Margit Zeher</name></author><author><name sortKey="Szegedi, Gyula" sort="Szegedi, Gyula" uniqKey="Szegedi G" first="Gyula" last="Szegedi">Gyula Szegedi</name></author><author><name sortKey="Kiss, Emese" sort="Kiss, Emese" uniqKey="Kiss E" first="Emese" last="Kiss">Emese Kiss</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:929F78DDEE3AA7C8E6F54F82BEE89454B00876E9</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1196/annals.1422.008</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-4WXXHL6G-K/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002B89</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002B89</idno><idno type="wicri:Area/Istex/Curation">002B89</idno><idno type="wicri:Area/Istex/Checkpoint">000A07</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000A07</idno><idno type="wicri:doubleKey">0077-8923:2007:Tarr T:occurrence:of:malignancies</idno><idno type="wicri:Area/Main/Merge">001B35</idno><idno type="wicri:Area/Main/Curation">001B24</idno><idno type="wicri:Area/Main/Exploration">001B24</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Occurrence of Malignancies in Hungarian Patients with Systemic Lupus Erythematosus</title><author><name sortKey="Tarr, Tunde" sort="Tarr, Tunde" uniqKey="Tarr T" first="Tünde" last="Tarr">Tünde Tarr</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Third Department of Medicine, Medical and Health Science Center, University of Debrecen, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author><author><name sortKey="Gyorfy, Balazs" sort="Gyorfy, Balazs" uniqKey="Gyorfy B" first="Balázs" last="Gyorfy">Balázs Gyorfy</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Third Department of Medicine, Medical and Health Science Center, University of Debrecen, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author><author><name sortKey="Szekanecz, Eva" sort="Szekanecz, Eva" uniqKey="Szekanecz E" first="Éva" last="Szekanecz">Éva Szekanecz</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Oncology, Medical and Health Science Center, University of Debrecen, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author><author><name sortKey="Bhattoa, Harjit Pal" sort="Bhattoa, Harjit Pal" uniqKey="Bhattoa H" first="Harjit Pal" last="Bhattoa">Harjit Pal Bhattoa</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Clinical Biochemistry and Molecular Pathology, Medical and Health Science Center, University of Debrecen, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author><author><name sortKey="Zeher, Margit" sort="Zeher, Margit" uniqKey="Zeher M" first="Margit" last="Zeher">Margit Zeher</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Third Department of Medicine, Medical and Health Science Center, University of Debrecen, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author><author><name sortKey="Szegedi, Gyula" sort="Szegedi, Gyula" uniqKey="Szegedi G" first="Gyula" last="Szegedi">Gyula Szegedi</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Third Department of Medicine, Medical and Health Science Center, University of Debrecen, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author><author><name sortKey="Kiss, Emese" sort="Kiss, Emese" uniqKey="Kiss E" first="Emese" last="Kiss">Emese Kiss</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Third Department of Medicine, Medical and Health Science Center, University of Debrecen, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Annals of the New York Academy of Sciences</title><title level="j" type="alt">ANNALS OF NEW YORK ACADEMY SCIENCES</title><idno type="ISSN">0077-8923</idno><idno type="eISSN">1749-6632</idno><imprint><biblScope unit="vol">1108</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="76">76</biblScope><biblScope unit="page" to="82">82</biblScope><biblScope unit="page-count">7</biblScope><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2007-06">2007-06</date></imprint><idno type="ISSN">0077-8923</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0077-8923</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Arthritis rheum</term><term>Autoimmune</term><term>Autoimmune diseases</term><term>Bernatsky</term><term>Bladder</term><term>Breast cancer</term><term>Cancer frequency</term><term>Cancer morbidity</term><term>Cancer prevalence</term><term>Cell proliferation</term><term>Cervix</term><term>Cervix cancer</term><term>Cohort</term><term>Data show</term><term>Debrecen</term><term>Direct correlation</term><term>Disease duration</term><term>Erythematosus</term><term>First years</term><term>Health science center</term><term>Hematologic</term><term>Hematologic malignancies</term><term>High risk</term><term>Hungarian lupus patients</term><term>Life expectancy</term><term>Lupus</term><term>Lupus diagnosis</term><term>Lupus onset</term><term>Lupus patients</term><term>Lymphoma</term><term>Lymphoma development</term><term>Major determinants</term><term>Malignancy</term><term>Malignant</term><term>Malignant disorders</term><term>Morbidity</term><term>Particular types</term><term>Patient examination</term><term>Rheum</term><term>Rheumatology</term><term>Screening measures</term><term>Skin cancer</term><term>Standardized incidence ratio</term><term>Study period</term><term>Such cases</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Third department</term><term>York academy</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">abstract: As a result of increasing life expectancy of lupus patients, malignant disorders have become major determinants of morbidity and mortality. The objectives of this study were to analyze cancer‐associated morbidity and mortality, the type of malignancies in Hungarian lupus patients, and to analyze association with immune‐suppressive therapy, disease duration, and age of the patients. Data from 860 systemic lupus erythematosus (SLE) patients were retrospectively analyzed in a study period between 1970 and 2004. Results were compared to data from age‐ and sex‐matched population obtained from the Health for All database, and also to literature data. A total of 37 patients presented with cancer, reflecting 4.3% cancer‐associated morbidity. Patients were 47 (20–73) years old at the onset of malignancy, which appeared 13 (1–45) years later than SLE. Cancer prevalence was the highest in the first 5–10 years of lupus. Breast cancer was the most common malignancy (n= 11) followed by gastrointestinal tumors (n= 9), cervix cancer and hematologic malignancies (n= 5 for both), bronchial cancer (n= 4), bladder, skin, and ovarian cancer (n= 1 for each). Standardized incidence ratio was the highest for non‐Hodgkin lymphoma (standardized incidence ratio [SIR] 3.5, 95%CI 0.4–12.5) and cervix cancer (SIR 1.7, 95%CI 0.6–4.1). Although 76% of patients with cancer received immune‐suppressive therapy besides corticosteroids, no direct correlation could be confirmed between therapy and malignancy. Out of the 164 patients that expired during the study period, 18 were cancer‐related. As such the cancer‐associated mortality was 11% (18/164). This peaked during the last 4 years of the study period (8/24, 33%). Lupus patients are at high risk for particular types of malignant disorders, highlighting the importance of screening measures and focused patient examination.</div></front></TEI><affiliations><list><country><li>Hongrie</li></country></list><tree><country name="Hongrie"><noRegion><name sortKey="Tarr, Tunde" sort="Tarr, Tunde" uniqKey="Tarr T" first="Tünde" last="Tarr">Tünde Tarr</name></noRegion><name sortKey="Bhattoa, Harjit Pal" sort="Bhattoa, Harjit Pal" uniqKey="Bhattoa H" first="Harjit Pal" last="Bhattoa">Harjit Pal Bhattoa</name><name sortKey="Gyorfy, Balazs" sort="Gyorfy, Balazs" uniqKey="Gyorfy B" first="Balázs" last="Gyorfy">Balázs Gyorfy</name><name sortKey="Kiss, Emese" sort="Kiss, Emese" uniqKey="Kiss E" first="Emese" last="Kiss">Emese Kiss</name><name sortKey="Szegedi, Gyula" sort="Szegedi, Gyula" uniqKey="Szegedi G" first="Gyula" last="Szegedi">Gyula Szegedi</name><name sortKey="Szekanecz, Eva" sort="Szekanecz, Eva" uniqKey="Szekanecz E" first="Éva" last="Szekanecz">Éva Szekanecz</name><name sortKey="Zeher, Margit" sort="Zeher, Margit" uniqKey="Zeher M" first="Margit" last="Zeher">Margit Zeher</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:929F78DDEE3AA7C8E6F54F82BEE89454B00876E9
|texte= Occurrence of Malignancies in Hungarian Patients with Systemic Lupus Erythematosus
}}
| This area was generated with Dilib version V0.6.33. |  |